In recent years, immunotherapy by checkpoint blockade targeting programmed cell death protein-1 [PD-1] or its ligand (programmed death ligand-1 [PD-L1]) has reshaped the treatment of advanced cancer around the world, showing remarkable clinical activity in several tumor types [1]. The gene discussed is PDCD1; the disease is neoplasm.